| Entry |
|
|---|
| Name |
Cevimeline hydrochloride (USAN);
Cevimeline hydrochloride hydrate (JAN);
Evoxac (TN);
Saligren (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
(C10H17NOS)2. 2HCl. H2O
|
|---|
| Exact mass |
488.1701
|
|---|
| Mol weight |
489.5633
|
|---|
| Structure |
   |
|---|
| Class |
Neuropsychiatric agent
DG01490 Muscarinic cholinergic receptor agonist
Other
DG01719 Parasympathomimetic agent
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 2399 |
| Product (DG00993): | D00661<JP/US> |
|
|---|
| Efficacy |
Salivation accelaletor, Muscarinic acetylcholine receptor agonist |
|---|
| Disease |
Sjögren's Syndrome [DS: H01502] |
|---|
| Comment |
Arecoline derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565], CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07A PARASYMPATHOMIMETICS
N07AX Other parasympathomimetics
N07AX03 Cevimeline
D00661 Cevimeline hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
Dental and Oral Agents
Cevimeline
D00661 Cevimeline hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
239 Miscellaneous
2399 Others
D00661 Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Acetylcholine (muscarinic)
CHRM3
D00661 Cevimeline hydrochloride (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00661
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00661
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00661
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00661
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 29
1 C1z C 24.9536 -15.4572
2 C1y C 24.9536 -14.0450
3 C1x C 23.6698 -16.2274
4 C1x C 23.6698 -13.2748
5 C1x C 24.0550 -14.9437
6 N1y N 22.3861 -15.4572
7 C1x C 22.3861 -14.0450
8 C1x C 23.4130 -14.4302
9 O2x O 24.9536 -16.8968
10 C1y C 26.3228 -17.3417
11 S2x S 27.1689 -16.1770
12 C1x C 26.3228 -15.0123
13 C1a C 26.7689 -18.7147
14 O0 O 31.1826 -14.4759
15 X Cl 31.0386 -16.9232
16 C1z C 24.9536 -15.4572
17 C1y C 24.9536 -14.0450
18 C1x C 23.6698 -13.2748
19 C1x C 22.3861 -14.0450
20 N1y N 22.3861 -15.4572
21 C1x C 23.6698 -16.2274
22 C1x C 23.4130 -14.4302
23 C1x C 24.0550 -14.9437
24 O2x O 24.9536 -16.8968
25 C1y C 26.3228 -17.3417
26 S2x S 27.1689 -16.1770
27 C1x C 26.3228 -15.0123
28 C1a C 26.7689 -18.7147
29 X Cl 31.0386 -16.9232
BOND 30
1 1 2 1
2 1 3 1
3 2 4 1
4 2 5 1
5 3 6 1
6 4 7 1
7 5 8 1
8 6 7 1
9 6 8 1
10 1 9 1 #Up
11 9 10 1
12 10 11 1
13 11 12 1
14 1 12 1
15 10 13 1 #Down
16 16 17 1
17 16 21 1
18 17 18 1
19 17 23 1
20 21 20 1
21 18 19 1
22 23 22 1
23 20 19 1
24 20 22 1
25 16 24 1 #Up
26 24 25 1
27 25 26 1
28 26 27 1
29 16 27 1
30 25 28 1 #Down
BRACKET 1 21.7000 -19.3900 21.7000 -12.8100
1 28.1400 -12.8100 28.1400 -19.3900
1 2
ORIGINAL 1 1 2 4 7 6 3 8 5 9 10 11 12 13
REPEAT 1 16 17 18 19 20 21 22 23 24 25 26 27 28
2 29.4700 -17.7800 29.4700 -15.9600
2 31.7100 -15.9600 31.7100 -17.7800
2 2
ORIGINAL 2 15
REPEAT 2 29
|
|---|
